| TELEMEdizinisches moNiTORing für COPD-Patienten (Telementor COPD): Studienprotokoll einer multizentrischen, randomisierten, kontrollierten Studie F Püschner, J Schiller, D Urbanski-Rini, K Scholl, A Bock, M Jandl, ... Pneumologie, 2024 | | 2024 |
| Airway specific deregulation of asthma-related serpins impairs tracheal architecture and oxygenation in D. melanogaster B Ehrhardt, H Angstmann, B Höschler, D Kovacevic, B Hammer, T Roeder, ... Scientific Reports 14 (1), 16567, 2024 | | 2024 |
| Nasal epithelial gene expression identifies relevant asthma endotypes in the ATLANTIS study T Karp, A Faiz, J van Nijnatten, HAM Kerstjens, I Boudewijn, M Kraft, ... Thorax, 2024 | | 2024 |
| Midregional Proatrial Natriuretic Peptide (MRproANP) is associated with vertebral fractures and low bone density in patients with chronic obstructive pulmonary disease (COPD) FC Trudzinski, RA Jörres, P Alter, H Watz, CF Vogelmeier, HU Kauczor, ... Respiratory Research 25 (1), 274, 2024 | | 2024 |
| Dupilumab for COPD with blood eosinophil evidence of type 2 inflammation SP Bhatt, KF Rabe, NA Hanania, CF Vogelmeier, M Bafadhel, ... New England Journal of Medicine 390 (24), 2274-2283, 2024 | 10 | 2024 |
| Sex differences in asthma control, lung function and exacerbations: the ATLANTIS study TM Kole, S Muiser, M Kraft, S Siddiqui, LM Fabbri, KF Rabe, A Papi, ... BMJ open respiratory research 11 (1), e002316, 2024 | | 2024 |
| Urinary eosinophil‐derived neurotoxin is associated with reduced lung function in pediatric asthma J Omony, C Thölken, A Salimi, K Laubhahn, S Illi, M Weckmann, ... Pediatric Allergy and Immunology 35 (6), e14172, 2024 | | 2024 |
| Dupilumab Improves Post-bronchodilator Lung Function in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation: Data From the … NA Hanania, SP Bhatt, KF Rabe, CF Vogelmeier, M Bafadhel, ... A27. EMERGING TREATMENTS AND THERAPEUTIC STRATEGIES IN COPD: RESULTS OF …, 2024 | | 2024 |
| In The Phase 3 Boreas Trial, Dupilumab Reduced FeNO Levels Over Time in Patients With Moderate-to-Severe COPD With Type 2 Inflammation SP Bhatt, SA Christenson, NA Hanania, M Bafadhel, KF Rabe, ... A27. EMERGING TREATMENTS AND THERAPEUTIC STRATEGIES IN COPD: RESULTS OF …, 2024 | | 2024 |
| Efficacy and Safety of Dupilumab in Patients With Moderate-to-Severe COPD and Type 2 Inflammation: Phase 3 NOTUS Trial SP Bhatt, KF Rabe, NA Hanania, CF Vogelmeier, M Bafadhel, ... B13. BREAKING NEWS: CLINICAL TRIAL RESULTS IN PULMONARY MEDICINE, A7517-A7517, 2024 | | 2024 |
| Impaired Left Ventricular Filling and All-cause Mortality in COPD B Waschki, H Watz, P Alter, K Kahnert, FC Trudzinski, E Groth, AM Kirsten, ... D93. LOOKING BEYOND THE LUNGS: COPD AND COMORBIDITIES, A7229-A7229, 2024 | | 2024 |
| Dupilumab Improves Pre-bronchodilator Lung Function Measures in Patients With Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation: Data From the Phase 3 … A Papi, NA Hanania, SP Bhatt, KF Rabe, CF Vogelmeier, M Bafadhel, ... A27. EMERGING TREATMENTS AND THERAPEUTIC STRATEGIES IN COPD: RESULTS OF …, 2024 | | 2024 |
| Dupilumab Does Not Impact Blood Eosinophil Levels in Patients With Moderate-to-Severe COPD and Type 2 Inflammation: From the Phase 3 Boreas Trial M Bafadhel, SA Christenson, NA Hanania, SP Bhatt, KF Rabe, ... A27. EMERGING TREATMENTS AND THERAPEUTIC STRATEGIES IN COPD: RESULTS OF …, 2024 | | 2024 |
| Sex-specific Differences in Patients With Mild COPD and Symptomatic (ex)-smokers at Risk-Baseline Data From Capto-COPD F Trinkmann, M Abdo, AM Kirsten, JD Michels, FC Trudzinski, KF Rabe, ... B80-2. ABNORMALITIES IN STRUCTURE AND FUNCTION IN COPD, A4533-A4533, 2024 | | 2024 |
| In the Phase 3 Boreas Trial, Baseline Blood Eosinophils and Baseline Fractional Exhaled Nitric Oxide Levels Predict the Response to Dupilumab in Patients With Moderate-to … S Christenson, NA Hanania, SP Bhatt, M Bafadhel, KF Rabe, ... C95. NEW CLINICAL TRIAL RESULTS IN CHRONIC LUNG DISEASE, A6620-A6620, 2024 | | 2024 |
| Tezepelumab in adults with moderate to very severe chronic obstructive pulmonary disease (COPD): efficacy and safety from the phase 2a COURSE study D Singh, M Bafadhel, CE Brightling, KF Rabe, MK Han, M Bhutani, ... B13. BREAKING NEWS: CLINICAL TRIAL RESULTS IN PULMONARY MEDICINE, A7516-A7516, 2024 | 2 | 2024 |
| Improved Annotation of Asthma Gene Variants With Cell Type Deconvolution of Nasal and Lung Expression-Quantitative Trait Loci Z Elhusseini, T Karp, T Gillett, C Qi, D Khalenkow, T Van der Molen, ... B71. ASTHMA PATHOGENESIS: MORE THAN MEETS THE EYE, A4327-A4327, 2024 | | 2024 |
| Dupilumab Increases the Proportion of Patients With Fractional Exhaled Nitric Oxide Levels< 20 ppb Over Time in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary … S Christenson, M Bafadhel, NA Hanania, SP Bhatt, KF Rabe, ... B52. EVIDENCE FOR THERAPEUTIC STRATEGIES IN COPD: FROM ESTABLISHED TO …, 2024 | | 2024 |
| Biomarkers associated with lung function decline and dupilumab response in patients with asthma ID Pavord, L De Prado Gómez, G Brusselle, DJ Jackson, CE Brightling, ... American Journal of Respiratory and Critical Care Medicine 209 (8), 1031-1033, 2024 | 4 | 2024 |
| 17q21 Variants disturb mucosal host defense in childhood asthma CA Jakwerth, M Weckmann, S Illi, H Charles, UM Zissler, M Oelsner, ... American journal of respiratory and critical care medicine 209 (8), 947-959, 2024 | 6 | 2024 |
